BeiGene Ltd. (BGNE) is a strong buy according to a predictive model with an accuracy of 0.67 for predicting an upward trend in the following two weeks. If a trader used this AI strategy between 2020-10-16 and 2023-08-23, they would have had a potential return of 438.31%, with an average of 27.39% and 34.0 days in the long position over the 16.0 positions taken. The analyst consensus price target is 302.55.
BeiGene, Ltd. is a biopharmaceutical company that focuses on the development, manufacturing, and commercialization of cancer therapeutics drugs. The company is headquartered in Beijing, the People’s Republic of China and has operations in the United States. BeiGene’s drug pipeline consists of both clinical-stage and preclinical-stage agents. The company’s current marketed products are Revlimid (lenalidomide) and Imbruvica (ibrutinib). The company’s marketed product portfolio also includes ZUMA-1, a CAR T cell therapy product. BeiGene has partnerships with international pharmaceutical companies such as Celgene and AbbVie.
BeiGene’s stock has had a volatile performance over the past few years, with the stock price fluctuating between highs of 280.62 and lows of 118.18. The stock is currently trading at 199.41 as of September 1, 2023. The company’s market capitalization stands at 25.38 billion and the stock has a price to book ratio of 4.67.
BeiGene’s revenue for the quarter ended September 30, 2022 was $124.98 million, an increase of 8.78% from the previous year. The company had a net loss of $182.04 million, an increase of 40.46% from the previous year. The company’s gross profit for the quarter was $44.78 million, a decrease of 5.36% from the previous year. The company’s earnings per share for the quarter was a loss of $20.05 and the price to sales ratio was 16.8.
Share Price Performance in Context of Current Share Price
BeiGene’s share price has seen an impressive run over the past year, rising from a low of 118.18 to its current price of 199.41. The company’s market capitalization stands at 25.38 billion and the stock has a price to book ratio of 4.67. The company’s analyst target price is 302.55, indicating significant upside potential for the stock.
Unnamed: 0: 0
AssetType: Common Stock
Name: BeiGene Ltd
Description: BeiGene, Ltd. discovers, develops, manufactures and markets cancer therapeutics drugs in the People’s Republic of China and the United States. The company is headquartered in Beijing, the People’s Republic of China.
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
Address: C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, KY
|Date||Symbol||Prediction||Model Accuracy||Price Target||Analyst Target|
More AI Trading NASDAQ Tue, 05 Sep buys
AI Trading NASDAQ Tue, 05 Sep sells
Back-testing and model summaries
Thanks for subscribing and happy investing!
The Third Perspective Team